- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06074692
PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) (PRIMA)
A Prospective Phase II Study of PARP Inhibition and Check Point-inhibition Immunotherapy With Concurrent Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic or Advanced Sarcoma
Study Overview
Status
Conditions
Detailed Description
Bone and soft tissue sarcomas are a group of highly heterogeneous malignant tumors that originate from mesenchymal tissue. The recurrent and metastatic sarcomas are usually refractory to traditional radiotherapy and chemotherapy, with a five-year survival rate is less than 20% to 30%. Therefore, novel therapy targeting the molecular phenotypic characteristics of bone and soft tissue sarcomas and conduct personalized and precise treatment for specific target patient subgroups is one of the important directions in the current clinical and translational fields.
Studies based on the anti-cancer mechanism of synthetic lethality have shown that tumor cells with BRCA1 or BRCA2 gene mutations are very sensitive to the action of PARP inhibitors. Interestingly, recent research results have shown that many other tumor types besides gynecological tumors can also exhibit BRCA-like phenotypes (BRCAness) and genomic instability (GI). Among them, BRCAness is a subtype of bone and soft tissue sarcoma with poor prognosis. Although such patients rarely carry BRCA gene mutations, they can still potentially benefit from treatment with drugs related to DNA damage and synthetic lethality, such as PARP inhibitors. In addition, the latest research shows that the BRCA-like phenotype in sarcoma is related to immunosuppression in its tumor microenvironment and targeted intervention of the PARP pathway is likely to have a potential immune sensitizing effect on the tumor microenvironment of sarcoma. Our previous study based on 264 samples also suggested that in sarcoma subtypes with genomic complexity, tumor cells often demonstrated high GI characteristics, and the corresponding tumor transcriptomes exhibited BRCAness. Furthermore, the investigators established 8 cases of patient-derived sarcoma primary cell model (PTCC) through tumor biopsy samples and observed a high sensitivity to DNA damage in sarcoma habouring BRCAness.
In recent years, studies have found that when radiotherapy is given to local tumor lesions, Abscopal effect could be elicited by the immunogenic death of the local tumor. The investigators recently reviewed the clinical prognosis of 44 patients with advanced bone and soft tissue sarcoma treated with stereotactic body radiation therapy (SBRT) in our institute and found that the tumor response rate to the immune checkpoint inhibitor appears to be significantly increased after SBRT. Based on these findings, the investigators speculate that the combination of SBRT and PARP inhibition regimens could potentially boost the immunogenic death and further improve the immunotherapy response in metastatic or advanced sarcomas.
In this clinical trial, the investigators aim to evaluate the efficacy and safety of PARP Inhibition and programmed cell death protein-1 (PD-1) blockade immunotherapy with concurrent stereotactic body radiotherapy (SBRT) for metastatic or advanced bone and soft tissue sarcoma as a phase II clinical study. Meanwhile, the investigators evaluated the patient's tumor gene mutation, homologous recombination deficiency (HRD) score, and RAD51 functional testing and other aspects for correlative biomarker exploration, providing a theoretical basis for molecular precision treatment of bone and soft tissue sarcoma with PARP inhibitiors.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Weibin Zhang, PhD, MD
- Phone Number: +8613501824630
- Email: zhangweibin10368@163.com
Study Contact Backup
- Name: Yuhui Shen, PhD, MD
- Phone Number: +8613918209875
- Email: yuhuiss@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 20025
- Recruiting
- Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine
-
Contact:
- Qiyuan Bao, MD., Ph.D
- Phone Number: +86 13818971504
- Email: rblw_110@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Written informed consent signed before any trial-related procedures are carried out
- Histologically confirmed high-grade sarcoma of bone or soft tissue; the lesion has distant metastasis or is locally advanced and cannot be completely resected at the time of enrollment, or the patient cannot tolerate or refuses surgical resection;
- Have received at least one systemic treatment regimen(s) at the time of enrollment, and have not received prior PARP inhibitor treatment.
- With measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST1.1);
- Aged no less than 10 years old and no more than 70 years old;
- For patients ≥16 years old, ECOG score is between 0 and 2 (for patients with amputations, if they can basically take care of themselves and can move freely for more than 50% of their waking hours with the assistance of stretchers, walkers, wheelchairs, etc.) still included);
- For patients under 16 years old, Lansky score is at least 70 or above (for patients with amputations who are unable to participate in active recreational activities due to amputation), if they can participate in most active recreational activities with the assistance of walkers, wheelchairs, etc., they are still eligible included).
- The expected survival time is greater than 24 weeks;
- The majority of the recurrent lesions with an established radiological diagnosis could receive SBRT;
- Major organ functions meet basic safety standards within 7-14 days before treatment.
- Women of childbearing age should agree that they must use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the end of the study; if in doubt, serum or urine tests within 7 days before study enrollment The pregnancy test is negative and the patient must be non-lactating; the male should agree that contraceptive measures must be used during the study period and within 6 months after the end of the study period;
If there are recurrent lesions previously treated by surgery, radiofrequency ablation or radiotherapy:
- If the image of the metastatic lesion is stable, enrollment is allowed and SBRT is not required for that lesion;
- If the metastatic lesion has image progression, if it was previously treated with surgery and SBRT can be performed, enrollment is allowed; if it was previously treated with radiofrequency ablation or radiotherapy, if repeat SBRT can be considered, enrollment is allowed.
Exclusion Criteria:
- Diagnosed with malignant diseases other than tumors within 5 years before the first dose;
- Currently participating in interventional clinical research treatment, or have received other research drugs or used research equipment within 4 weeks before the first dose;
- Previously received the following therapies: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs targeting another stimulating or synergistic inhibition of T cell receptors (e.g., CTLA-4, OX-40, CD137) drug and secondary resistance to the drug (i.e., the best efficacy evaluation is CR, PR or SD lasting more than 4 months, but secondary tumor resistance develops after treatment).
- Received systemic systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects (including thymosin, interferon, interleukin, except local use to control pleural effusion) within 2 weeks before the first dose;
- Active autoimmune disease requiring systemic treatment (such as use of disease-modifying drugs, glucocorticoids, or immunosuppressants) within 2 years before the first dose. Replacement therapies (such as thyroxine, insulin, or physiological glucocorticoids for adrenal or pituitary insufficiency, etc.) are not considered systemic treatments;
- Are receiving systemic glucocorticoid treatment (excluding nasal spray, inhaled or other route of topical glucocorticoids) or any other form of immunosuppressive therapy within 7 days before the first dose of the study;
- Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation;
- Known to be allergic to any components of monoclonal antibody preparations (have experienced grade 3 or above allergic reactions);
- Have not fully recovered from toxicity and/or complications caused by any intervention before initiating treatment (i.e., ≤Grade 1 or reaching baseline, excluding fatigue or alopecia);
- Known history of human immunodeficiency virus (HIV) infection (i.e. HIV1/2 antibody positive);
- Get live vaccine within 30 days before the first dose (cycle 1, day 1);
- Pregnant or lactating women;
- Any serious or uncontrollable systemic disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bone arm
Bone tumor subgroup (bone arm) includes high-grade osteosarcoma, chondrosarcoma, undifferentiated bone sarcoma and other rare bone sarcomas with complex genomic features..
|
Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
|
Experimental: Soft tissue arm
Soft tissue sarcoma subgroup (soft tissue arm) includes leiomyosarcoma, pleomorphic rhabdomyosarcoma, angiosarcoma, fibrosarcoma, epithelioid sarcoma, malignant peripheral nerve sheath tumor(MPNST) and other rare soft tissue sarcomas with complex genomic features.
|
Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
|
Experimental: UPS/DDLPS arm
Immune hot tumor subgroup (UPS/DDLPS arm) includes undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDLPS).
|
Patients receive Camrelizumab (PD-1 inhibitor) and fluzoparib (PARP inhibitor) with concurrent stereotactic body radiotherapy (SBRT)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-momth progression-free survival rate (6m-PFSR)
Time Frame: 6 months from recruitment
|
The proportion of patients that are progression-free according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1), defined as the ratio of patients who have not died or progressed (CR+PR+SD) over the total number of subjects recruited.
|
6 months from recruitment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective respones rate (ORR)
Time Frame: From baseline to disease progression or death, whichever occurs first, until 3 years after accrual
|
Defined as the number of subjects with a best response of (CR+PR)/total number of subjects*100% based on RECISTv1.1 and irRECIST standards respectively
|
From baseline to disease progression or death, whichever occurs first, until 3 years after accrual
|
Disease control rate (DCR)
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Defined as the number of subjects with a best response of (CR+PR+SD)/total number of subjects*100% based on RECISTv1.1 and irRECIST standards respectively;
|
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Duration of response (DOR)
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Defined as the interval from first time of response (CR or PR) until disease progression (PD) according to RECISTv1.1 and irRECIST standards respectively, and estimated by the Kaplan-Meier method, including median, Interquartiles and 95% confidence intervals
|
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Progression-free survival (PFS)
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Defined as the time from receiving the first study drug to the death or relapse of the subject, assessed by RECISTv1.1 and irRECIST standards respectively, and estimated by the Kaplan-Meier method, including median, quartile and 95% confidence interval
|
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Overall survival (OS)
Time Frame: From baseline until the reported death of the patients due to any causes, up to 3 years after accrual
|
defined as the time from receiving the first study drug treatment to the subject's death, estimated by the Kaplan-Meier method, including median, quartile and 95% confidence interval;
|
From baseline until the reported death of the patients due to any causes, up to 3 years after accrual
|
Quality of life assessed by patient-reported outcomes (PROs)
Time Frame: From baseline until the reported death of the patients due to any causes, up to 3 years after accrual
|
The quality of life score using PROs based on EORTC QLQ-C30 scale (adult) or Paediatric Quality of Life Inventory (PedsQL) scale at baseline and at each followed up after treatment.
|
From baseline until the reported death of the patients due to any causes, up to 3 years after accrual
|
Number of participants with adverse events
Time Frame: From the first dose of study treatment to 30 days after the last dose of study treatment or before the start day of new anti-cancer drug therapy, whichever occurs first, up to 3 years.
|
Number of participants with Treatment emergent adverse events (TEAE) and serious adverse events (SAE).
AE was defines as any toxicities in a participant who received study therapy irrespective of the causal relationship.
SAE was defined as one of the following: was fatal or life-threatening; resulted in persistent or significant disability/incapacity or inpatient hospitalization or prolongation of existing hospitalization.
|
From the first dose of study treatment to 30 days after the last dose of study treatment or before the start day of new anti-cancer drug therapy, whichever occurs first, up to 3 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory outcome: progression-free survival(PFS) in different subgroup
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual.
|
The PFS for each subgroups in terms of clinicopathological and genomic characteristics (age, gender, histological type, solitary or multiple metastases, unilateral or bilateral metastases, early or late metastases, calcifying or non-calcifying lesions, with or without lesion cavitation, with or without AEs, etc.
|
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual.
|
Exploratory outcome: the homologous recombination deficiency (HRD) score in tumor samples
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
The correlative relationship between the tumor response and the genomic biomarker (i.e. homologous recombination-related [HRR] gene mutation, homologous recombination deficiency (HRD) score (LOH+TAI+LST), and RAD51 functional testing) and the therapeutic outcome. |
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual
|
Exploratory outcome: the expression of immune infiltration biomarker in tumor samples
Time Frame: From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual.
|
Tumor microenvironment change (immune infiltration, PD-1/PD-L1 expression, immunogenic death, etc.) pre- and post- SBRT, and conduct correlative analysis between these immune microenvironment indeces and the therapeutic outcome.
|
From baseline to disease progression or death, whichever occurs first, up to 3 years after accrual.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Weibin Zhang, PhD, MD, Ruijin Hospital
- Principal Investigator: Yuhui Shen, PhD, MD, Ruijin Hospital
- Principal Investigator: Qiyuan Bao, PhD, MD, Ruijin Hospital
- Principal Investigator: Junxiang Wen, PhD, MD, Ruijin Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2023-LLS-220
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcoma
-
Albert Einstein College of MedicineNational Cancer Institute (NCI)TerminatedUterine Corpus Leiomyosarcoma | Stage IIA Uterine Sarcoma | Stage IIB Uterine Sarcoma | Stage IIIA Uterine Sarcoma | Stage IIIB Uterine Sarcoma | Stage IIIC Uterine Sarcoma | Stage IVA Uterine Sarcoma | Stage IVB Uterine Sarcoma | Stage IA Uterine Sarcoma | Stage IB Uterine Sarcoma | Stage IC Uterine SarcomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedBone Sarcoma | Retroperitoneal Sarcoma | Adult Soft Tissue SarcomaUnited States
-
Mohammed M MilhemGenentech, Inc.CompletedSarcoma | Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Metastatic Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Unresectable SarcomaUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Brown UniversityActuate Therapeutics Inc.WithdrawnSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell SarcomaUnited States
-
Centre Oscar LambretFrench Sarcoma Group; Study Group of Bone TumorsCompletedSoft Tissue Sarcoma | Uterine SarcomaFrance
-
Epizyme, Inc.RecruitingAdvanced Soft-tissue Sarcoma | Advanced Epithelioid SarcomaUnited States, Taiwan, Canada, United Kingdom
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
Clinical Trials on Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
-
Sun Yat-sen UniversityGuangdong Provincial People's Hospital; Affiliated Cancer Hospital & Institute... and other collaboratorsRecruitingNasopharyngeal CarcinomaChina
-
The Netherlands Cancer InstituteCompletedLung Cancer | Metastatic Lung CancerNetherlands, United States, Canada, Germany
-
Chongqing University Cancer HospitalRecruitingNasopharyngeal CarcinomaChina
-
Duke UniversityGateway for Cancer ResearchActive, not recruiting
-
European Organisation for Research and Treatment...UnknownNon-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIGermany, Belgium, United Kingdom, Switzerland
-
Memorial Sloan Kettering Cancer CenterRecruitingBreast Cancer | Metastatic Breast Cancer | ER+ Breast Cancer | Metastatic Breast Carcinoma | HER2+ Breast Cancer | Oligometastatic Breast CarcinomaUnited States
-
Istituto Clinico HumanitasRecruiting
-
Royal North Shore HospitalRecruiting
-
Regina Elena Cancer InstituteAzienda Sanitaria-Universitaria Integrata di Udine; San Giovanni Addolorata...Recruiting
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting